PHAT logo

PHATHOM PHARMACEUTICALS INC

PHATNASDAQ
πŸ† #2978 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track PHAT
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$379M
Small Cap
πŸ“ˆRevenue Growth (YoY)
216.9%
High Growth
πŸ“ŠGross Margin
80.7%
High
πŸ’΅FCF Margin
-7.7%
Thin
βš–οΈP/S Ratio
1.4x
Cheap
Otter Score
76
Strong
No chart data available for PHAT.

Trading Snapshot

Day Range
β€”
52-Week Range
$4.62 – $18.31
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
81.3M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$175M
Last Q Revenue
$85M
P/E Ratio
-4.5
P/S Ratio
1.4x
EPS (TTM)
$-0.98
Dividend Yield
0.00%
Dilution (1yr)
+3.9%
PHAT logo

PHATHOM PHARMACEUTICALS INC

PHAT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$175Mβ–² +216.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
87.1%β–² +1.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$160Mβ–Ό βˆ’42.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$167Mβ–Ό βˆ’37.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
73.8Mβ–² +3.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$82Mβ–Ό βˆ’$177M YoY
StockOtter Β· stockotter.space

About PHATHOM PHARMACEUTICALS INC

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

News unavailable.